Gold River Productions Inc (GRPS): Other than stating they are going to sta...

Other than stating they are going to stay

Anvil · 2025-03-07T16:09:37.7300000Z

Other than stating they are going to stay in biz and still having 5 employees that are being paid scraps, with $112 in cash, I don't see a lot going on. JMO

Play Episode

4min

Proactive - Interviews for investors

ATOME signs milestone EPC deal with Casale for Villeta project

ATOME PLC (AIM:ATOM) CEO Olivier Mussat talked with Proactive about a landmark milestone for the company’s Villeta green fertiliser project in Paraguay. The company has signed its first definitive engineering, procurement and construction (EPC) agreement with Swiss firm Casale S.A. Mussat explained that this agreement marks the world’s first large-scale green hydrogen fertiliser project to reach the EPC stage, underlining its global relevance. “It’s significant for us as a company because we’ve announced that we had been working on the front-end engineering and design for more than two years now,” Mussat said, noting the long-term collaboration with Casale. He highlighted Casale’s industry-leading expertise, describing the firm as the oldest ammonia licensor globally, with the ability to deliver complex, full-chain fertiliser projects. According to Mussat, the partnership serves as a strategic blueprint for Casale’s future growth. Looking ahead, ATOME aims to reach a final investment decision on the Villeta project by the end of the first half of the year. The company is working to finalise offtake agreements and complete financial documentation for both debt and equity funding. This includes a $115 million equity commitment from Hy24, with further syndication in progress. For more updates on green hydrogen and clean energy developments, visit Proactive’s YouTube channel. Like this video, subscribe, and turn on notifications to stay informed. #ATOMEPLC #GreenHydrogen #EPCContract #FertilizerProject #Casale #SustainableEnergy #CleanTech #HydrogenEconomy #ParaguayProjects #Yara #Hy24

Proactive - Interviews for investors

Ananda Develops U.S. presence as lead drug advances to Phase 1 clinical study

Ananda Pharma CEO Melissa Sturgess joined Steve Darling from Proactive to announce the company’s shares have begun trading on the OTCQB market in the United States, a strategic move that expands Ananda’s visibility and access to U.S. investors. The UK-based biopharmaceutical company is focused on developing regulatory-approved cannabinoid medicines for complex and chronic medical conditions. Sturgess emphasized the significance of entering the U.S. market, not only from a capital markets perspective but also as a key future territory for Ananda’s clinical and commercial ambitions. She also highlighted recent progress in the company’s clinical development pipeline, particularly around its lead investigational drug candidate, MRX1. Ananda recently received approval from the Alfred Hospital Human Research Ethics Committee in Australia to initiate a Phase 1 pharmacokinetic study of MRX1. The study will evaluate the safety, tolerability, and pharmacokinetics of two dose levels of the CBD-based drug in a cohort of 20 healthy adult volunteers—10 biological males and 10 biological females—to address known sex differences in CBD metabolism. MRX1 is a high-purity, pharmaceutical-grade cannabidiol (CBD) formulation developed under rigorous quality standards to ensure consistency, safety, and clinical reliability. It is intended for the treatment of chronic inflammatory pain conditions, where current treatment options often fall short in efficacy or come with undesirable side effects. Sturgess noted that this ethics approval marks a critical milestone in the company’s journey toward regulatory approval and commercial readiness. The trial is expected to generate key safety and dosing data to support future Phase 2 studies targeting patients with unmet needs in chronic pain management. #proactiveinvestors #aqse #ana #cbd #otcqb #MRX1 #CBDDrugDevelopment #CannabinoidTherapy #ClinicalTrials #FDAApproval #PharmaNews #BiotechStocks #OTCQB #GWPharma #CBDMedicine #ChronicPainTreat

Proactive - Interviews for investors

European Green Transition co-founder Cathal Friel outlines growth strategy as he takes chair

European Green Transition PLC (AIM:EGT) founder and non-executive chairman Cathal Friel talked with Proactive's Stephen Gunnion about his formal move into the non-executive chairman role and the company’s strategy going forward. Friel shared how European Green Transition (EGT) aims to build value by acquiring distressed yet revenue-generating assets, a model he has successfully applied with previous companies such as Amryt Pharma and hVIVO. “Our model going forward is to acquire low-priced, distressed, good value assets, bolt them together,” he said, emphasising the need for revenue-generating components or the capacity to make acquisitions profitable from day one. He reflected on EGT’s IPO in April 2024 and his transition from other responsibilities, including his long tenure with hVIVO. With that chapter closed, he now brings more focus to EGT’s growth. Friel confirmed that the company still holds the majority of the £6.5 million raised, having only used a small portion on its rare earth asset in Sweden. Monetising that asset remains a priority. EGT's strategy continues to centre on small teams, tight cost control, and targeting multi-fold returns over a 24-month horizon. “I’ll be very careful of [the shareholders’] cash. It’s like mine,” Friel added. Visit Proactive’s YouTube channel for more interviews. Don’t forget to like this video, subscribe, and turn on notifications so you never miss an update. #CathalFriel #EuropeanGreenTransition #EGT #RareEarths #MergersAndAcquisitions #SmallCapInvesting #GreenEconomy #MiningInvestment #ShareholderValue #hVIVO #AmrytPharma #IPO

Proactive - Interviews for investors

Ananda Pharma adds former GW Pharmaceuticals executive as strategic advisor, advances MRX1

Ananda Pharma Plc finance director Jeremy Sturgess-Smith talked with Proactive's Stephen Gunnion about the appointment of Chris Tovey as a strategic advisor. Tovey brings significant experience from his time as chief operating officer at GW Pharmaceuticals and later Jazz Pharmaceuticals. According to Sturgess-Smith: “He’s going to bring all that experience to Ananda,” helping guide the company through its regulatory path and corporate development. Sturgess-Smith also touched on Ananda securing ethics approval to begin its first human trial of MRX1, a key milestone for the company’s therapeutic pipeline. He noted this was the first ethics approval of its kind for any Ananda trial, with recruitment expected to begin shortly in Australia. “It’s very, very exciting to have that ethics approval in the bag,” he said. Looking ahead, the company also expects ethics approvals for studies into chemotherapy-induced peripheral neuropathy and endometriosis in the next six months. For more interviews and updates, visit Proactive's YouTube channel. Don’t forget to like this video, subscribe, and hit the notification bell to stay informed.** #AnandaPharma #MRX1Trial #ClinicalTrials #CannabinoidMedicine #BiotechNews #PharmaceuticalInnovation #EthicsApproval #GWPharma #DrugDevelopment #Epidiolex #HealthInnovation #ProactiveInvestors

Followers	146
Posts	22364
Boards Moderated	1
Alias Born	10/07/2007

Volume:	-
Day Range:
Bid:	0.0001
Ask:	0.0002
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

GRPS Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free